NASDAQ:SRNE
Delisted
Sorrento Therapeutics Stock News
$0.307
+0 (+0%)
At Close: Feb 23, 2023
Sorrento Therapeutics: Sales Are Up But EY Identifies Internal Control Issues
03:27pm, Tuesday, 15'th Mar 2022
Sorrento Therapeutics' revenues are up 33% year-on-year.
IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss, Misses Revenue Estimates
11:15am, Tuesday, 15'th Mar 2022 Zacks Investment Research
IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of -51.61% and 70.76%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the
AquaBounty Technologies, Inc. (AQB) Reports Q4 Loss, Misses Revenue Estimates
02:45pm, Thursday, 10'th Mar 2022 Zacks Investment Research
AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of 0% and 56.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the s
Sorrento Therapeutics Sees Positive Results for Covid-19 Neutralizing Antibody
05:23pm, Wednesday, 02'nd Mar 2022 MarketWatch
By Chris Wack Sorrento Therapeutics Inc. said Wednesday that new preclinical results demonstrate that pretreating an animal with intranasal neutralizing…
SRNE stock higher on FDA nod for clinical trial for COVID-19 therapy (SRNE)
05:02pm, Wednesday, 02'nd Mar 2022 Seeking Alpha
San Diego, California-based biotech Sorrento Therapeutics <> announced on Wednesday that the U.S
Sorrento Announces COVISHIELD (STI-9199) Antibody Nasal Drops Prevent Productive SARS-CoV-2 Infections When Given 24 Hours Prior to Virus Exposure
04:37pm, Wednesday, 02'nd Mar 2022 GlobeNewswire Inc.
SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that new preclinical results demonstrate that pretreating an animal with intranas
Sorrento Announces FDA Authorization to Proceed With Phase 1 Study Of Intranasal STI-9199 (COVISHIELD), a Potent Neutralization Antibody Against Covid-19 Viruses
04:24pm, Wednesday, 02'nd Mar 2022 GlobeNewswire Inc.
SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that it has received clearance from the FDA for its investigational new drug appl
Is Sorrento Therapeutics Inc. (NASDAQ: SRNE) Stock Set To Rise More?
07:00pm, Tuesday, 01'st Mar 2022 Marketing Sentinel
In the latest trading session, 1.64 million Sorrento Therapeutics Inc. (NASDAQ:SRNE) shares changed hands as the company’s beta touched 2.37. With the company’s most recent per share price at $2.48 changed hands at -$0.05 or -1.98% at last look, the market valuation stands at $801.98M. SRNE’s current price is a discount, trading about -346.37% off … Is Sorrento Therapeutics Inc. (NASDAQ: SRNE) Stock Set To Rise More? Read More »
With 1.92% Distance From Low, Is Sorrento Therapeutics Inc. (NASDAQ:SRNE) Poised For More Gains?
02:30pm, Friday, 25'th Feb 2022 Marketing Sentinel
In last trading session, Sorrento Therapeutics Inc. (NASDAQ:SRNE) saw 10.7 million shares changing hands with its beta currently measuring 2.33. Company’s recent per share price level of $2.61 trading at $0.05 or 1.95% at ring of the bell on the day assigns it a market valuation of $829.61M. That closing price of SRNE’s stock is … With 1.92% Distance From Low, Is Sorrento Therapeutics Inc. (NASDAQ:SRNE) Poised For More Gains? Read More »
Zymeworks Inc. (ZYME) Reports Q4 Loss, Tops Revenue Estimates
11:20pm, Thursday, 24'th Feb 2022 Zacks Investment Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 10.38% and 56.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Sorrento'' COVISHIELD shows neutralizing activity vs Omicron subvariants
03:37pm, Tuesday, 22'nd Feb 2022 Seeking Alpha
Sorrento Therapeutics <> said additional preclinical results showed broad spectrum COVISHIELD (STI-9167) neutralizing activity against Omicron BA.1, Omicron BA.1+R346K, and
SRNE stock slips after acquiring majority stake in FortuneBio to meet COVID-19 test demand
07:01pm, Thursday, 17'th Feb 2022 Seeking Alpha
Sorrento Therapeutics (SRNE) announced the acquisition of Chinese-based diagnostic test maker, Zhengzhou Fortune Bioscience. Read more on reasons.
Sorrento Therapeutics Buys Majority Stake in Diagnostic Test Maker
06:20pm, Thursday, 17'th Feb 2022 MarketWatch
By Chris Wack Sorrento Therapeutics Inc. said Thursday it bought a majority ownership of diagnostic manufacturer Zhengzhou Fortune Bioscience Co. The company…
Sorrento Announces That It Has Acquired a Majority Ownership in Diagnostic Manufacturer Zhengzhou Fortune Bioscience in Response to Increasing Worldwide Demand For COVISTIX™
06:02pm, Thursday, 17'th Feb 2022 GlobeNewswire Inc.
SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the acquisition of a majority ownership of Zhengzhou Fortune Bioscience Co., Ltd.
Sorrento Therapeutics Inc. (NASDAQ: SRNE) On Wednesday – Up 8.2 Percent From Lows, What To Expect Going Ahead?
02:30pm, Thursday, 17'th Feb 2022 Marketing Sentinel
During the last session, Sorrento Therapeutics Inc. (NASDAQ:SRNE)’s traded shares were 4.17 million, with the beta value of the company hitting 2.30. At the end of the trading day, the stock’s price was $3.05, reflecting an intraday loss of -2.24% or -$0.07. The 52-week high for the SRNE share is $14.51, that puts it down … Sorrento Therapeutics Inc. (NASDAQ: SRNE) On Wednesday – Up 8.2 Percent From Lows, What To Expect Going Ahead? Read More »
